Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
1.
J Vasc Interv Radiol ; 30(7): 1004-1012, 2019 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-31171399

RESUMO

PURPOSE: To retrospectively investigate the safety and benefit of gefitinib plus transarterial infusion (TAI) therapy as a first-line treatment compared to gefitinib alone for patients with large (>7 cm) nonsmall cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. MATERIALS AND METHODS: Between January 2010 and December 2013, 92 consecutive treatment-naïve patients with large NSCLC with EGFR mutations, who were treated using gefitinib plus TAI (G+T, n = 42) or gefitinib alone (G, n = 50) were reviewed. The primary endpoints were the objective response rate (ORR) and tumor reduction rate. The secondary endpoints were progression-free survival (PFS) and overall survival (OS), and safety was also assessed. RESULTS: The baseline characteristics of the 2 groups were balanced, and no patients experienced treatment-related death. Toxicity outcomes did not differ between the G+T and G groups. The tumor reduction rate in the G+T group was significantly higher than that in the G group (42.9 vs 31.9%, P = .028). The ORR was 83% in the G+T group and 72% in the G group (P = .197). The median PFS was significantly longer in the G+T group than in the G group (14.0 vs 10.0 months, P = .023). The median OS was 30.0 months in the G+T group and 27.0 months in the G group (P = .235). CONCLUSIONS: This study suggests that compared with gefitinib alone, combination therapy with gefitinib plus TAI was well tolerated and potentially improved the tumor reduction rate and PFS in patients with large NSCLC with EGFR mutations.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Cisplatino/administração & dosagem , Gefitinibe/administração & dosagem , Neoplasias Pulmonares/tratamento farmacológico , Mutação , Inibidores de Proteínas Quinases/administração & dosagem , Adolescente , Adulto , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Carcinoma Pulmonar de Células não Pequenas/genética , Carcinoma Pulmonar de Células não Pequenas/mortalidade , Carcinoma Pulmonar de Células não Pequenas/patologia , Cisplatino/efeitos adversos , Receptores ErbB/antagonistas & inibidores , Receptores ErbB/genética , Feminino , Gefitinibe/efeitos adversos , Humanos , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/mortalidade , Neoplasias Pulmonares/patologia , Masculino , Pessoa de Meia-Idade , Intervalo Livre de Progressão , Inibidores de Proteínas Quinases/efeitos adversos , Estudos Retrospectivos , Fatores de Risco , Fatores de Tempo , Carga Tumoral , Adulto Jovem
2.
J Vasc Interv Radiol ; 29(12): 1654-1661, 2018 12.
Artigo em Inglês | MEDLINE | ID: mdl-30396842

RESUMO

PURPOSE: To evaluate the value of α-fetoprotein (AFP) classification criteria in predicting tumor response and patient survival and to discuss the agreement between AFP criteria and modified Response Evaluation Criteria In Solid Tumors (mRECIST). MATERIALS AND METHODS: Between January 2011 and December 2014, 147 patients with unresectable hepatocellular carcinoma (HCC) with baseline AFP levels ≥ 400 ng/mL who underwent transarterial chemoembolization as initial treatment were retrospectively enrolled for AFP/imaging correlation analysis. AFP-based response was classified as complete response (CR) in cases of AFP level normalization, partial response (PR) in cases of > 50% decrease vs baseline, stable disease (SD) in cases of -50% to +30% change vs baseline, or progressive disease (PD) in cases of > 30% increase vs baseline. Intermethod agreement between the 2 methods was assessed by Cohen κ coefficient. Response rates according to AFP and mRECIST were compared, and the association between response rate and overall survival (OS) was evaluated. RESULTS: The κ value for agreement between AFP criteria and mRECIST was 0.549 (ie, moderate), with objective response and disease control rates of 36.1% and 63.3% per AFP criteria and 34.7% and 46.3% per RECIST (P = .807 and P = .003), respectively. Although AFP criteria and mRECIST showed significantly prognostic strata for CR, PR, SD, and PD after chemoembolization (P < .001 for both), some overlap in radiologic PD survival curves was observed. The OS of AFP-based disease control (ie, CR/PR/SD) was significantly longer than that of AFP-based PD among patients with radiologic PD (9.0 vs 6.0 mo; P < .001). CONCLUSIONS: The defined AFP response moderately correlated with mRECIST response and yielded accurate prognostic prediction in patients with HCC and AFP levels ≥ 400 ng/mL treated with chemoembolization.


Assuntos
Carcinoma Hepatocelular/tratamento farmacológico , Quimioembolização Terapêutica/métodos , Técnicas de Apoio para a Decisão , Neoplasias Hepáticas/tratamento farmacológico , Critérios de Avaliação de Resposta em Tumores Sólidos , alfa-Fetoproteínas/metabolismo , Adulto , Carcinoma Hepatocelular/sangue , Carcinoma Hepatocelular/diagnóstico , Carcinoma Hepatocelular/mortalidade , Quimioembolização Terapêutica/efeitos adversos , Quimioembolização Terapêutica/mortalidade , Tomada de Decisão Clínica , Feminino , Humanos , Neoplasias Hepáticas/sangue , Neoplasias Hepáticas/diagnóstico , Neoplasias Hepáticas/mortalidade , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Reprodutibilidade dos Testes , Estudos Retrospectivos , Medição de Risco , Fatores de Risco , Fatores de Tempo , Tomografia Computadorizada por Raios X
3.
Zhongguo Zhong Xi Yi Jie He Za Zhi ; 35(8): 1011-4, 2015 Aug.
Artigo em Chinês | MEDLINE | ID: mdl-26485920

RESUMO

The essence of endogenous turbidity in Chinese medicine (CM) is different from cream, fat, phlegm, retention, damp, toxicity, and stasis. Along with the development of modern scientific technologies and biology, researches on the essence of endogenous turbidity should keep pace with the time. Its material bases should be defined and new connotation endowed at the microscopic level. The essence of turbidity lies in abnormal functions of zang-fu organs. Sugar, fat, protein, and other nutrient substances cannot be properly decomposed, but into semi-finished products or intermediate metabolites. They are inactive and cannot participate in normal material syntheses and decomposition. They cannot be transformed to energy metabolism, but also cannot be synthesized as executive functioning of active proteins. If they cannot be degraded by autophagy-lysosome or ubiquitin-prosome into glucose, fatty acids, amino acids, and other basic nutrients to be used again, they will accumulate inside the human body and become endogenous turbidity. Therefore, endogenous turbidity is different from final metabolites such as urea, carbon dioxide, etc., which can transform vital qi. How to improve the function of zang-fu organs, enhance its degradation by autophagy-lysosome or ubiquitin-prosome is of great significance in normal operating of zang-fu organs and preventing the emergence and progress of related diseases.


Assuntos
Medicina Tradicional Chinesa , Autofagia , Humanos , Complexo de Endopeptidases do Proteassoma
4.
Hum Immunol ; 75(10): 1062-8, 2014 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-25223469

RESUMO

BACKGROUND: The association between ADIPOQ polymorphisms and the risk of obesity remains controversial. We perform a comprehensive meta-analysis to clarify the current understanding of this association. METHODS: We searched for relevant studies in PubMed, Embase and Cochrane library before February 2014. The strengths of the association between ADIPOQ polymorphisms and obesity risk were estimated by odds ratios (OR) with 95% confidence intervals (CI). RESULTS: Eighteen case-control studies analyzing four SNPs (rs17300539, rs266729, rs1501299 and rs2241766) of ADIPOQ gene were eligible for the present meta-analysis. The pooling results showed that rs17300539 (2GG+GA vs. 2AA+GA: OR=0.78, 95%CI=0.69-0.89) and rs1501299 (2GG+GA vs. 2AA+GA: OR=0.89, 95%CI=0.80-0.98) were associated with obesity risk in Caucasian ethnicity. The rs266729 were associated with obesity risk in Asian ethnicity (2CC+CG vs. 2GG+GCG: OR=0.77, 95%CI=0.65-0.92). However, there were no associations between rs2241766 and the obesity risk (P>0.05). No publication bias was found among these studies (all P>0.05). CONCLUSIONS: This study suggests that ADIPOQ rs17300539 and rs1501299 are associated with risk of obesity in Caucasian ethnicity, and the rs266729 is associated with obesity risk in Asian ethnicity. However, there is no association between rs2241766 and obesity risk.


Assuntos
Adiponectina/genética , Povo Asiático , Obesidade/genética , População Branca , Estudos de Associação Genética , Predisposição Genética para Doença , Estudo de Associação Genômica Ampla , Humanos , Polimorfismo de Nucleotídeo Único , Risco
5.
Cancer Lett ; 344(2): 239-59, 2014 Mar 28.
Artigo em Inglês | MEDLINE | ID: mdl-24280585

RESUMO

Plumbagin (PLB) has shown anti-cancer activity but the mechanism is unclear. This study has found that PLB has a potent pro-apoptotic and pro-autophagic effect on A549 and H23 cells. PLB arrests cells in G2/M phase, and increases the intracellular level of reactive oxygen species in both cell lines. PLB dose-dependently induces autophagy through inhibition of PI3K/Akt/mTOR pathway as indicated by reduced phosphorylation of Akt and mTOR. Inhibition or induction of autophagy enhances PLB-induced apoptosis. There is crosstalk between PLB-induced apoptosis and autophagy. These findings indicate that PLB initiates both apoptosis and autophagy in NSCLC cells through coordinated pathways.


Assuntos
Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Neoplasias Pulmonares/tratamento farmacológico , Naftoquinonas/farmacologia , Inibidores de Fosfoinositídeo-3 Quinase , Proteínas Proto-Oncogênicas c-akt/antagonistas & inibidores , Serina-Treonina Quinases TOR/antagonistas & inibidores , Apoptose/efeitos dos fármacos , Autofagia/efeitos dos fármacos , Carcinoma Pulmonar de Células não Pequenas/patologia , Linhagem Celular Tumoral , Humanos , Neoplasias Pulmonares/patologia , Sistema de Sinalização das MAP Quinases/efeitos dos fármacos , Fosfatidilinositol 3-Quinases/metabolismo , Proteínas Proto-Oncogênicas c-akt/metabolismo , Serina-Treonina Quinases TOR/metabolismo
6.
Zhongguo Zhen Jiu ; 33(6): 561-4, 2013 Jun.
Artigo em Chinês | MEDLINE | ID: mdl-23967654

RESUMO

The theoretical basis, location, belonging of zang-fu, treatment function and indications, applying principle and manipulation of Umbilical Ring acupoints in Zhuang medicine are explained in this paper. According to Zhuang medicine, umbilicus is an epitome of the body and all the zang-fu and organs in the body have corresponding epitomes like a fetus in front-standing position. The umbilicus is not only a micro-diagnosis system, but also a window for illness treatment that could be divided into superficial, middle and deep layer to respectively communicate different zang-fu and organs. The umbilical inner ring and outer ring are collectively called Umbilical Ring acupoints, they could dredge paths, regulate the balance of qi and blood to regulate qi, expel poison, tonify deficiency and remove stasis to treat many types of diseases in the whole body.


Assuntos
Pontos de Acupuntura , Terapia por Acupuntura , Umbigo , Humanos , Medicina Tradicional Chinesa , Umbigo/anatomia & histologia
7.
Zhong Yao Cai ; 34(8): 1247-50, 2011 Aug.
Artigo em Chinês | MEDLINE | ID: mdl-22233041

RESUMO

OBJECTIVE: To develop a method for determination the content of Potassium Sodium Dehydroandroan drographolide Succinate (PSDS) in rat intestinal contents and plasma and investigate the intestinal absorption of PSDS pellets in rat and in vivo pharmacokinetics of PSDS pellets. METHODS: The content of PSDS in rat intestinal contents and plasma was determined by HPLC. In vivo pharmacokinetic properties and intestinal absorption of PSDS pellets in rat were investigated. RESULTS: Two hours after administration, pellets were not found in the small intestine and large intestine, four hours after administration, the largest number of pellets were found in the small intestine and the concentration of PSDS was the highest in the intestinal contents (3593.13 microg). The characteristics of plasma concentration-time curve was consistent with a single compartment model. The main drug pharmacokinetic parameters were calculated. t1/2, T(max), C(max) and AUC were 2.69 h, 5 h, 3.02 microg/mL and 6.42 microg x h/mL, respectively. CONCLUSION: PSDS has a good absorption in the rat small intestine and it is feasible to prepare PSDS enteric-coated pellets for oral administration.


Assuntos
Andrographis/química , Anti-Inflamatórios não Esteroides/farmacocinética , Diterpenos/farmacocinética , Absorção Intestinal , Intestino Delgado/metabolismo , Administração Oral , Animais , Anti-Inflamatórios não Esteroides/administração & dosagem , Anti-Inflamatórios não Esteroides/sangue , Área Sob a Curva , Disponibilidade Biológica , Cromatografia Líquida de Alta Pressão , Diterpenos/administração & dosagem , Diterpenos/sangue , Feminino , Intestino Grosso/metabolismo , Ratos , Ratos Wistar , Ácido Succínico/sangue , Ácido Succínico/química , Ácido Succínico/farmacocinética , Comprimidos com Revestimento Entérico , Fatores de Tempo
8.
Zhong Yao Cai ; 33(3): 455-8, 2010 Mar.
Artigo em Chinês | MEDLINE | ID: mdl-20681316

RESUMO

OBJECTIVE: To establish a suitable formulation for the dispersible tablets of brevisicapine. METHODS: To prepare and optimize the breviscapine dispersible tablets by orthogonal experiment design using disintegration time as the index. The quality of breviscapine dispersible tablets was evaluated by the initial stability test. RESULTS: The disintegration time of optimized prescription formulation was 89 s. L-HPC and CMS-Na were used by combining exterior and interior and the dissolution percent in vitro was obviously superior to the conventional tablets, and the quality of the dispersible tablets was very good in stability test. CONCLUSION: The formulation screened out for the dispersible tablets of breviscapine is reasonable, stable and suitable for the production on a large scale.


Assuntos
Anticoagulantes/administração & dosagem , Química Farmacêutica/métodos , Erigeron/química , Flavonoides/administração & dosagem , Anticoagulantes/química , Estabilidade de Medicamentos , Medicamentos de Ervas Chinesas/administração & dosagem , Medicamentos de Ervas Chinesas/química , Excipientes/administração & dosagem , Excipientes/química , Flavonoides/química , Solubilidade , Comprimidos , Fatores de Tempo
10.
Nan Fang Yi Ke Da Xue Xue Bao ; 29(6): 1240-2, 2009 Jun.
Artigo em Chinês | MEDLINE | ID: mdl-19726373

RESUMO

OBJECTIVE: To explore the therapeutic effects of amiodarone and metoprolol, either alone or in combination, on chronic heart failure (CHF) complicated by ventricular arrhythmia. METHODS: A total of 110 NYHA class II-III patients with CHF complicated by ventricular arrhythmia were randomly divided into amiodarone group, metoprolol group and amiodarone + metoprolol group. The therapeutic effects was evaluated at the end of the 1-year follow-up. RESULTS: Amiodarone, metoprolol and their combination produced statistically different therapeutic effects (P<0.05). Compared with amiodarone and metoprolol used alone, amiodarone combined with metoprolol resulted in significant cardiac function improvement (P<0.05) and ventricular arrhythmia control (P<0.01). During the 1-year follow-up, the readmission rate and cardiac event rate in the amiodarone + metoprolol group were significantly lower than those in amiodarone group (P<0.01) and metoprolol group (P<0.05). The adverse reaction rates in the 3 groups were similar (P>0.05). CONCLUSION: The combination of amiodarone and metoprolol produces better effect than amiodarone or metoprolol alone in the treatment of CHF complicated by ventricular arrhythmia.


Assuntos
Amiodarona/uso terapêutico , Insuficiência Cardíaca/tratamento farmacológico , Metoprolol/uso terapêutico , Taquicardia Ventricular/tratamento farmacológico , Complexos Ventriculares Prematuros/tratamento farmacológico , Antagonistas Adrenérgicos beta/uso terapêutico , Adulto , Antiarrítmicos/uso terapêutico , Doença Crônica , Quimioterapia Combinada , Feminino , Insuficiência Cardíaca/complicações , Insuficiência Cardíaca/fisiopatologia , Humanos , Masculino , Taquicardia Ventricular/etiologia , Taquicardia Ventricular/fisiopatologia , Resultado do Tratamento , Complexos Ventriculares Prematuros/etiologia
11.
Zhong Yao Cai ; 29(9): 970-3, 2006 Sep.
Artigo em Chinês | MEDLINE | ID: mdl-17212058

RESUMO

To prepare and optimize the gastrodin dispersible tablets by orthogonal design using the disintegration time as index. The quality of gastrodin dispersible tablets was evaluated by the initial stability test. The results showed that the disintegration time of optimized prescription formulation was 106s, i.e. L-HPC and CMS-Na was used by combining exterior and interior and the dissolution percent in vitro was obviously super to the conventional tablets. Moreover, the quality of the dispersible tablets was very well by stability test.


Assuntos
Álcoois Benzílicos/administração & dosagem , Medicamentos de Ervas Chinesas/administração & dosagem , Glucosídeos/administração & dosagem , Excipientes Farmacêuticos/administração & dosagem , Plantas Medicinais/química , Tecnologia Farmacêutica/métodos , Área Sob a Curva , Álcoois Benzílicos/química , Química Farmacêutica , Estabilidade de Medicamentos , Medicamentos de Ervas Chinesas/química , Glucosídeos/química , Lactose/administração & dosagem , Excipientes Farmacêuticos/química , Excipientes Farmacêuticos/classificação , Solubilidade , Comprimidos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...